Cited 0 times in
Phase III study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+metastatic breast cancer (HER2CLIMB-05, trial in progress)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.